The present application relates to an attenuated oncolytic virus strain, an oncolytic virus vaccine and a drug for treating tumors by combining the oncolytic virus vaccine with immune cells. The present application provides a new attenuated oncolytic virus strain by a site-directed mutation of a matrix protein M of a VSV wild-type virus. On the basis of the attenuated oncolytic virus strain, the present application further provides a vaccine that can be used in tumor treatment. On the basis of the vaccine, the present application further provide a drug that can effectively treat multiple kinds of tumors by combining the vaccine with immune cells.

Described herein are compositions for delivering single-domain antibodies or antigen-binding fragments thereof to a subject. The single-domain antibodies may be therapeutic agents for treatment of a disease or a condition in the subject, such as a disease or a condition of affecting the lungs of the subject. The compositions comprise enucleated cells that are extensively engineered to produce the single-domain antibodies or antigen-binding fragment thereof, and optionally, contain additional components, such as a targeting moiety, immune system evading moiety, or additional therapeutic agents or adjuvants. Methods of producing the compositions described herein are provided, which involve methods of enucleating a parent cell to obtain the enucleated cell comprising the single-domain antibody or antigen-binding fragment thereof. Also provided are kits and methods for using the compositions described herein to treat the disease or a condition by administering one or more of the compositions to the subject.

The present disclosure provides hybrid promoter sequences comprising an MND promoter and HTLV enhancer capable of driving high levels of sustained expression of a heterologous sequence in immune cells, particularly Natural Killer (NK) cells. The disclosure also provides compositions comprising such vectors, immune cells which have been genetically modified to contain the vectors, as well as methods of using the same for inducing immune responses and treating cancer and other conditions.

Compounds, compositions, and methods for generating T cells with altered phenotype are disclosed. The phenotype-altered T cells have increased persistence, prolonged survival, and increased antitumor activity and are useful for treatment of cancers.

Provided are a DNA nanovaccine, a preparation method therefor and the use thereof. The DNA nanovaccine comprises a DNA nanostructure, a tumor antigen polypeptide-DNA complex and an immunologic adjuvant, and the immunologic adjuvant comprises a double-stranded RNA immunologic adjuvant and/or a CpG immunologic adjuvant. In the present invention, a nanostructure is constructed, wherein the nanostructure is assembled from a DNA template, a DNA chain for assisting in folding and a capture DNA chain. By hybridizing the capture DNA chain with a functional component, the precise positioning and assembling of a tumor antigen molecule and an immunologic adjuvant molecule on the surface of the DNA self-assembled nanostructure is realized; in addition, a controllable DNA molecule “switch” is designed on one side of the tubular DNA nanostructure, which switch can respond to the acid environment of an endosome after entering an antigen-presenting cell, and open the tubular structure responsively to release the tumor antigen and the immunologic adjuvant molecule. The nanostructure has a tumor antigen-specific immunostimulatory effect and is a tumor vaccine used for the immunotherapy and prevention of various types of malignant tumors.

Composition and methods for ex vivo expansion of natural killer (NK) cells, and methods for cell-based cancer immunotherapy are disclosed. Leukemic cell-derived dendritic cells and anti-PD-L1 antibodies, and certain embodiments with addition of PBMCs are used for in vivo administration for cancer treatment. Leukemic cell-derived dendritic cells and anti-PD-L1 antibodies are also used for ex vivo expansion of NK cells.

A tumor complex antigen, a multivalent dendritic cell (DC) vaccine, and a use thereof are provided. In the present disclosure, monocytes of a patient are stimulated in vitro, loaded with a variety of tumor cell lysates with strong immunogenicity against different Epstein-Barr virus (EBV)-associated tumors, and induced into mature dendritic cells (mDCs) by various cytokines and specific agonists to obtain a complete DC vaccine with corresponding tumor antigens. The DC vaccine can be injected back into the patient to activate an immune system, stimulate innate immunity (such as inducing natural killer (NK) cells), and stimulate lymphocytes to produce an acquired immune response and cytotoxic T cells, thereby accurately killing tumor cells. Compared with radiotherapy and chemotherapy, the DC vaccine is particularly safe and has almost no side effects. In addition, the production of the DC vaccine involves a short production cycle of about 1 week and a low cost.

A method of treating a Philadelphia chromosome-positive tumor in a subject comprises administering to the subject a therapeutic composition comprising an incubated combined mixture of (a) a first component comprising (i) Philadelphia chromosome-positive tumor lysate, (ii) plasmid encoding bcr/abl fusion protein, or (iii) bcr/abl fusion peptide; and (b) a second component comprising plasmacytoid dendritic cells expressing Toll-like receptor 9 and modified for stable expression of CD40 ligand or GM-CSF by a nucleotide sequence engineered into said plasmacytoid dendritic cells.

Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.